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Abstract: Background: Natural products are characterized by a complex chemical composition and 
are capable of concurrently modulate several signalling pathways. Considering the biological com-
plexity of carcinogenesis, natural products represent key components of the therapeutic armamen-
tarium for oncological diseases. The bark of Terminalia arjuna is used in traditional Ayurvedic 
medicine for its astringent, expectorant, cardiotonic, styptic, and antidysenteric properties. Along-
side its traditional uses, Terminalia arjuna exhibits different biological activities including an-
timutagenic and anticarcinogenic. 
Objective: This study was designed to evaluate the toxic effects of an alcoholic extract obtained 
from the bark of T. arjuna on a human T-lymphoblastic cell line (Jurkat). We explored the phyto-
chemical composition and investigated the cytotoxic, cytostatic, genotoxic, and anti-genotoxic effects.  
Methods: The phytochemical composition was analyzed using spectrophotometric methods; all the 
biological endpoints were assessed through flow cytometry.  
Results: The phytochemical screening showed that polyphenols represent about 64% of the extract. 
Moreover, the extract was cytotoxic on Jurkat cells by inducing both apoptosis and necrosis, and 
blocked the cell cycle in the G2/M phase. Additionally, it was found that the extract lacks any geno-
toxic effect, but was not effective in protecting Jurkat cells from the DNA damage induced by H2O2 
and etoposide.  
Conclusion: The results of our study show the toxic effects of Terminalia arjuna on Jurkat cells 
and confirm the pivotal role played by natural compounds in the oncological field. Further studies 
should be performed to better understand its clinical potential and deepen its toxicological profile. 
Keywords: Terminalia arjuna, leukemia cells, cytotoxicity, cell cycle, genotoxicity, antigenotoxicity. 
1. INTRODUCTION 
 Cancer is one of the worst plagues of this new millen-
nium. In 2018 it was responsible for an estimated 9.6 million 
deaths and about 18 million new cases of cancer were diag-
nosed [1]. 
 Carcinogenesis involves a series of definable and repro-
ducible stages that leads to the transformation of normal 
cells into cancerous cells [2]. The first phase, called initia-
tion, is characterized by the acquisition of mutations in sev-
eral different genes (oncogenes); the second stage, i.e. pro-
motion, is characterized by the selective clonal expansion of 
initiated cells to create a pre-neoplastic lesion, which could 
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phenotypically evolve in a malignant lesion during the final 
stage of carcinogenesis called progression [2]. Because can-
cer is a multifactorial disease, the shortcoming of many 
therapeutic drugs that interact with a single target could be 
overcome by using multi-target agents [3], which interact 
simultaneously with different biological targets. 
 Since ancient times, natural products have played a cen-
tral role in the treatment and prevention of human diseases 
[4]. Moving on to the last century, many plant compounds 
have a key role in anticancer therapy. Vincristine and vin-
blastine, for example, are two alkaloids with anticancer 
properties isolated from the Madagascar periwinkle  
(Catharanthus roseus) in the 1960s, which are still used to 
treat various cancers [5]. Another important anticancer drug is 
taxol, isolated from the bark of Pacific yew (Taxus brevifolia) 
by the National Cancer Institute (NCI) in the year 1971. 
Taxol has become one of the most used drugs for breast and 
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nowadays nature continues to be a great wealth of natural 
molecules with beneficial activities, especially in the on-
cological area: indeed, 175 small molecules were approved 
between 1940s and the end of 2014, of which 49% are either 
natural or directly derived from natural products [7]. The 
reason why natural products are so widely studied as poten-
tial anticancer drugs could be found in their great biodiver-
sity and, in particular, in their complex chemical composi-
tion. Since they are composed of countless molecules, they 
are able to interact with many different molecular targets and 
modulate various biological pathways [8-13]. Considering 
the multiple steps involved in the tumorigenesis process, 
natural products represent key components of the therapeutic 
armamentarium for oncological diseases. Moreover, given 
that the occurrence of resistance remains a major obstacle to 
tumour management [14], compounds capable of concur-
rently modulating several signalling pathways, as natural 
products, could help overcoming chemoresistance. 
 Terminalia arjuna (T. arjuna), also called “Arjun” in 
Hindi and “Bengali” and “Arjuna” in Sanskrit [15], is an 
indigenous large woody plant belonging to the family Com-
bretaceae [16], commonly found throughout the Indian pen-
insula. T. arjuna is an important traditional plant widely used 
in Ayurvedic medicine and mentioned in many ancient In-
dian medicinal texts [17]. In particular, the bark was tradi-
tionally used for its astringent, demulcent, expectorant, car-
diotonic, styptic, and antidysenteric properties; additionally, 
it has been shown to be useful in the treatment of fractures, 
ulcers, leukorrhea, diabetes, anemia, cardiopathy and cirrho-
sis [18]. The bark decoction has also been used for snakebite 
and scorpion sting [19]. Besides its traditional uses, a large 
and growing body of literature has investigated the pharma-
cological activities of T. arjuna. The plant exhibits antimi-
crobial [20, 21], antiviral [22], hypolipidemic [23, 24], car-
dioprotective [25-27], antioxidant [21, 24, 28-30], an-
timutagenic, and anticarcinogenic activities [30-36]. 
 In this framework, the aim of this study was to deepen 
the therapeutic potential of this medicinal plant evaluating 
whether it is toxic for cancer cells. In particular, we analyzed 
the phytochemical composition and explored the cytotoxic, 
cytostatic and antigenotoxic activities of an alcoholic extract 
obtained from the bark of T. arjuna on a human T-
lymphoblastic cell line (Jurkat). 
2. MATERIALS AND METHODS 
2.1. Plant Extract Preparation 
 The bark of T. arjuna was collected during the balsamic 
period (winter) and authenticated by Dr. Paolo Scartezzini, 
Maharishi Ayurveda Product Ltd., Noida, India. The quality 
control was performed by Vedic Herbs s.r.l. (Caldiero, VR, 
Italy), which gifted us with a sample of bark powder 
(voucher #12/11). Ten g of T. arjuna powder was mixed 
with 100 mL of 100% ethanol. To remove insoluble mate-
rial, the T. arjuna ethanolic extract (TAEE) was centrifuged. 
2.2. Determination of Total Phenolic Content 
 The Total Phenolic Content (TPC) of TAEE was deter-
mined using Folin-Ciocalteu reagent. It was performed in 
triplicate using a ThermoSpectronic Helios-γ spectropho-
tometer (Waltham, Massachusetts, USA), according to a 
previously described method [37]. The results of TPC were 
expressed as milligram gallic acid equivalents (GAE) per g 
of dry extract using a calibration curve of gallic acid. 
2.3. Total Flavonoids Determination 
 The Total Flavonoid Content (TFC) was measured by a 
colorimetric assay, as previously described by Lamaison & 
Carnet [38]. Briefly, an aliquot (1 mL) of the diluted sample 
or standard solution of hyperoside (0, 10, 20, 30, 40, 50, 60 
µg/mL) was added to a 1 mL of AlCl3·6H2O (2% w/v in 
methanol). After 10 min under stirring into the dark, the ab-
sorbance of the mixture was determined at 394 nm with a 
ThermoSpectronic Helios-γ spectrophotometer (Waltham, 
Massachusetts, USA). The evaluation was performed in trip-
licate, and the total flavonoids content was expressed as mg 
hyperoside equivalents (HE) per g of dry extract, using a 
calibration curve of hyperoside. 
2.4. Total Proanthocyanidins Determination 
 The Total Proanthocyanidins Content (TPrC) was meas-
ured by a colorimetric assay, as previously described by Por-
ter et al. [39]. Briefly, an aliquot (1 mL) of the diluted sam-
ple or standard solution of cyanidin chloride (0, 10, 20, 30, 
40, 50, 60 µg/mL) was added to a 6 mL of n-butanol/HCl 
(95:5) and 0.2 ml of a 2% solution of NH4Fe(SO4)2·12H2O 
in HCl 2M. The solution was kept 40 min under stirring at 
95°C. After cooling, the absorbance of the mixture was de-
termined at 550 nm with a ThermoSpectronic Helios-γ spec-
trophotometer (Waltham, Massachusetts, USA). The evalua-
tion was performed in triplicate, and the total proanthocya-
nidins content was expressed as mg cyanidin chloride 
equivalents (CCE) per g of dry extract, using a calibration 
curve of cyanidin chloride. 
2.5. Cell Cultures and Treatments 
 Human T-lymphoblastic cells (Jurkat) and human lym-
phocyte cells (TK6) were provided from LGC standards 
(LGC Group, Middlesex, UK). Cells were cultured in Ros-
well Park Memorial Institute (RPMI) 1640 medium supple-
mented with 10% heat-inactivated bovine serum, 1% penicil-
lin/streptomycin solution, and 1% l-glutamine solution (All 
obtained from Sigma Aldrich). Cells were maintained at 
37°C and 5% CO2 in a humidified atmosphere. To maintain 
exponential growth, Jurkat and TK6 cells were cultured 
without exceeding the maximum cell density of 3 X 106 mL 
and 1 X 106 mL, respectively. 
 Cells were treated with increasing concentration (0 - 1.00 
mg/mL) of TAEE for 1, 3, 6, or 24 h depending on experimental 
conditions. Etoposide (10 µM or 10 µg/mL) and H2O2 (1 mM) 
(All obtained from Sigma Aldrich) were used as positive controls. 
2.6. Analysis of Cell Viability 
 The determination of cell viability was performed using 
Guava ViaCount Reagent (Merck Millipore, Burlington, 
MA, USA) according to manufacturer’s instructions. Briefly, 
cells were incubated with the reagent containing 7-amino-
actinomycin D (7-AAD) and, after incubation at room tem-
perature in the dark for 5 minutes, cells were analyzed by 
flow cytometry. 
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2.7. Analysis of Cell Death Mechanisms 
 To discriminate between apoptotic and necrotic events, 
Guava Nexin Reagent (Merck Millipore) was used. This 
reagent, containing 7-AAD and annexin V-phycoerythrin 
(PE) is able to discriminate apoptotic and necrotic events. 
After incubation of 20 minutes at room temperature in the 
dark cells were analyzed by flow cytometry. Three cell 
populations can be detected: live cells (annexin V −/7-AAD 
−), early apoptotic cells (annexin V +/7-AAD −), and late 
apoptotic or necrotic cells (annexin V +/ 7-AAD +). 
2.8. Cell-Cycle Analysis 
 The percentages of cells in G0/G1, S, and G2/M phases 
were quantified by the analysis of DNA content using Guava 
Cell Cycle Reagent (Merck Millipore). After treatment with 
TAEE for 24 h, cells were fixed with 70% ice-cold ethanol; 
after washing, cells were suspended in 200 μL Guava Cell 
Cycle Reagent, containing propidium iodide, and incubated 
30 minutes at room temperature in the dark before analysis 
by flow cytometry. 
2.9. Analysis of DNA Damage 
 In order to assess the genotoxic potential of TAEE, phos-
phorylation of histone γ-H2A.X was evaluated as marker of 
DNA double strand breaks. In brief, after treatment of 6 h 
with TAEE, cells were fixed, permeabilized and incubated 
for 30 minutes in the dark at room temperature with an anti 
γ-H2A.X-Alexa Fluor® (Merck Millipore). Etoposide 10 μM 
was used as a positive control. Samples were analyzed via 
flow cytometry. 
 Furthermore, in addition to the primary damage to the 
DNA, the mutational effects of TAEE were evaluated 
through the micronucleus assay. Jurkat cells were treated 
with TAEE (0 – 0.40 mg/mL) for 24 h. At the end of the 
treatment, 0.5 × 106 cells were stained following the manu-
facturer’s instruction of the In Vitro Microflow kit (Litron 
Laboratories, Rochester, NY, USA). Cells were firstly 
stained with nucleic acid dye A solution containing ethidium 
monoazide (EMA). EMA, after photoactivation, is able to 
cross the damaged membrane of dead cells. Afterwards, 
complete lysis solution 1 and then lysis solution 2, which 
also contains SYTOX green, a chromatin dye, were added in 
order to digest the cytoplasmatic membrane and have the 
complete release of nuclei and micronuclei (MN). The dou-
ble staining of chromatin with EMA and SYTOX green al-
lows the discrimination between nuclei and MN in living 
cells (SYTOX green+) from fragments derived from dam-
aged chromatin of dead/dying cells (EMA+ /SYOTX green+). 
At the end of the incubation, cells were analyzed by flow 
cytometry. The discrimination between nuclei and MN has 
been performed through the analysis of their size (MN are 
smaller than nuclei) and their fluorescence (MN display 
1/100th to 1/10th of the intensity of duplicated nuclei [40]). 
2.10. Analysis of Antigenotoxic Activity 
 To assess the ability of TAEE to protect against DNA 
damage induced by different genotoxic agents, two different 
experimental settings were used. In the first one, cells were 
treated with TAEE before the exposure to the genotoxic 
agent (pre-treatment protocol); in the second one, cells were 
treated with TAEE during the exposure to the genotoxic 
agent (co-treatment protocol), as reported below: 
- In the pre-treatment protocol, cells were treated with 
TAEE 0.40 or 0.80 mg/mL. After 3 h, the culture 
medium was eliminated, and cells were treated with 
the genotoxin. After 1 h, cell samples were analyzed. 
- In the co-treatment protocol, cells were treated at the 
same time with TAEE 0.40 or 0.80 mg/mL plus the 
genotoxin for 1 h; then, cell samples were analyzed. 
 For H2O2 treatment, cells were treated in Phosphate Buff-
ered Saline (PBS) 1X. The analysis of histone γ-H2A.X 
phosphorylation was performed as described above. 
2.11. Flow Cytometry 
 All flow cytometric analyses were performed using an 
EasyCyte 5HT flow cytometer (Guava Technologies-
Millipore, Hayward, CA, USA). 
2.12. Statistical Analysis 
 All results are expressed as mean ± SEM of at least three 
independent experiments. Differences between treatments 
were assessed by one-way ANOVA, using Dunnet or Bon-
ferroni as post-tests. All statistical analyses were performed 
using GraphPad InStat 5.0 version (GraphPad Prism, San 
Diego, CA, USA, 2007). P < 0.05 was considered signifi-
cant. 
3. RESULTS AND DISCUSSION 
3.1. TAEE Contains Phenols, Flavonoids and Proantho-
cyanidins 
 T. arjuna bark alcoholic extract (TAEE) is known to con-
tain a large amount of phenols with important biological 
activities. Among them, the flavonoid luteolin and oli-
gomeric proanthocyanidins [41] are known to be co-
responsible for the multi-target potential of the extract to-
wards carcinogenesis [42-45]. Moreover, the phenols con-
tained in TAEE are also important because of their recog-
nised anti-mutagenic activity [35]. Therefore, to assess the 
bioactivity of the phytocomplex in relation to the content of 
these molecules, we measured the total phenolic content 
(TPC), total flavonoids content (TFC) and total proantho-
cyanidins content (TPrC) through spectrophotometric meth-
ods. The TPC (Table 1), expressed as gallic acid equivalent 
(GAE)/g of dried extract, has been shown to represent the 
64.46 % of the extract. The value of TPC reported in this 
study is lower than that reported by Viswanatha et al., who 
found about 90% for the alcoholic extract [35]. This discrep-
ancy could be due to the different extraction methods used. 
As stated above, among the phenolic compounds, literature 
reports the presence of flavonoids and proanthocyanidins 
[41]. Accordingly, we found a noteworthy presence of 
proanthocyanidins, expressed as cyanidin chloride equivalent 
(CCE)/g of dried extract. In particular, proanthocyanidins 
represent about one third of the TPC of TAEE (235,49±6,58 
mg CCE/g dried extract). Saha et al. [46] report a TPrC 
lower than that measured in our study (7,5 % against 23,5 
%), but they analyzed a different extract (aqueous instead of 
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alcoholic extract). Finally, the quantification of the TFC, 
expressed as hyperoside equivalents (HE)/g of dried extract, 
evidenced a low flavonoids content, which represents the 0.7 
% of the T. arjuna dried extract. Comparing the results of 
our study with those reported in literature, we can observe a 
noteworthy increase in proanthocyanidins in TAEE (from 7 
to 23%), which could be critical for the expression of the 
multi-target potential of T. arjuna towards carcinogenesis. 
3.2. TAEE Exhibits Cytotoxic Activity Against Jurkat 
Cells But Not Against TK6 Cells 
 Jurkat cells were treated with increasing concentrations 
of TAEE (0 - 1.00 mg/mL) for 24 h. After this treatment 
period, we observed a dose-dependent decrease of cell vi-
ability, reaching 56% at the highest tested concentration 
(Fig. 1A). 
 One of the major limitations of current anticancer chemo-
therapy is the inability to selectively induce cytotoxic effects 
on cancer cells. The cytotoxicity of antitumor drugs for non-
tumorigenic cells is associated with causing systemic toxic-
ity and significant side effects [47, 48]. Hence, the identifica-
tion of new anticancer agents that are selective towards can-
cer cells, thus with a better toxicological profile, is crucially 
important. The activity of TAEE was also tested on non-
tumorigenic cells in order to preliminary assess its selectivity 
towards tumour cells. No cytotoxic effect was observed on 
TK6 cells (Fig. 1B) after treatment for 24 h with increasing 
concentrations of TAEE. Those results indicate a favourable 
toxicological profile of the alcoholic extract. 
3.3. TAEE Induces Apoptosis and Necrosis 
 In order to investigate the mechanism responsible for the 
cytotoxic effect of TAEE, we used the annexin V/7-AAD 
assay. Phosphatidylserine (PS) exposure represents a crucial 
stage during the apoptotic process. Annexin V binding to PS 
allows detecting apoptotic cells (annexin V +/7-AAD − 
cells) [49]. 7-AAD can detect necrotic cells (annexin V +/ 7-
AAD + cells) due to its ability to permeate only cells with 
cell membrane damaged [50]. 
 The treatment with increasing concentrations of TAEE 
increased the fraction of apoptotic cells. An increase in the 
fraction of the necrotic cells was also observed (Fig. 2). The 
percentage of apoptotic cells started to increase from the 
concentration 0.20 mg/mL (7% versus 1.7% in untreated 
cells), and further increased up to the highest tested concen-
trations, where they reached about 29%. Alongside the in-
crease in apoptotic cells, an increment in the fraction of ne-
crotic cells was observed as well, starting from the concen-
tration of 0.20 mg/mL. The percentage of annexin V +/7-
AAD + cells was comparable to the apoptotic percentage: at 
the 0.80 mg/mL, for example, it was 25% compared to 29% 
of apoptotic cells (Fig. 2). 
 Cell death is a fundamental process that regulates several 
processes and is essential to maintain tissue homeostasis and 
to wipe out potentially harmful cells [51]. Cell death is gen-
erally classified into two main categories: 1) apoptosis, 
where cells exhibit cytoplasmic shrinkage, chromatin con-
densation (pyknosis), nuclear fragmentation (karyorrhexis), 
and plasma membrane blebbing. Apoptotic cells are effi-
ciently eliminated by neighbouring cells with phagocytic 
activity and lysosomal degradation [52]; 2) necrosis is a 
process characterized by the swelling of organelles, the rup-
ture of the plasma membrane, and the lysis of the cell, which 
culminates with cell corpse removal without obvious phago-
cytic and lysosomal activities [52]. Of note, apoptosis repre-
sents the most characterized form of programmed cell death, 
while necrosis is considered an uncontrolled type of cell 
Table 1. Quantification of total polyphenols, total flavonoids and total proanthocyanidins of T. arjuna ethanolic extract. 
Total Phenols mg GAE/g dried extract Total Flavonoids mg HE/g dried extract Total Proanthocyanidins mg CCE/g dried extract 
644,57±23,21 71,07±0,82 235,49±6,58 
 
 
Fig. (1). Percentage (%) of viable cells after 24 h treatment of Jur-
kat cells (A) or TK6 cells (B) with increasing concentrations of 
TAEE. ** p < 0.01; *** p < 0.001 versus untreated cells.  
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death [53]. However, in recent years several other forms of 
cell death have been discovered revealing that a cell can die 
via a number of different pathways [54]. 
 Anticancer therapeutic approaches based exclusively on 
apoptosis induction are frequently unsuccessful due to the 
activation of resistance mechanisms. Moreover, tumour pa-
thology is characterized by high genetic and genomic insta-
bility, which contribute to the mutation of some of the mo-
lecular actors involved in the apoptotic pathway and their 
inactivation. Accumulated evidence suggests that necrosis, 
especially when in concomitance with apoptosis, could rep-
resent an alternative mechanism to induce cancer cell death 
[55]. Furthermore, necrotic cell death is characterized by an 
inflammatory component that could stimulate an immune 
response raising the efficacy of tumour cell eradication [55]. 
Given that inflammatory response induced by necrotic cell 
death can be related to the onset of toxic effects, a balance 
between apoptosis and necrosis induction may thus be modu-
lated to enhance the immune response in cancer cells [55]. For 
instance, many chemicals have been found to induce cancer 
cell eradication through necrosis, such as β-lapachone, apop-
tolidin, and honokiol [56-59]. Nevertheless, a concomitant 
induction of apoptosis and necrosis seems to be induced es-
pecially by plant extracts, since they are composed of a com-
plex mixture of multiple active compounds that can act in a 
synergistic way to impair different biological pathways. 
 Our research findings reveal that TAEE treatment in-
duced both apoptosis and necrosis in a similar extent. Even if 
the removal of cancer cells in a regulated manner is more 
desirable, we could consider TAEE as an anticancer strategy 
potentially capable of overcoming an eventual failure in 
apoptotic induction. 
 A number of recent studies focused on the potential anti-
cancer effects of T. arjuna extract and its isolated compounds. 
In this regard, methanol and acetone extracts obtained from 
the bark of this medicinal plant were investigated on os-
teosarcoma cells (U20S) and gliobastoma cells (U251), 
where they showed growth inhibition by p53-dependent and 
-independent pathways [60]. Moreover, Shalini and col-
leagues observed an antiproliferative activity for T. arjuna 
bark methanolic extract and its phytosome on human breast 
adenocarcinoma cells (MCF-7) [61]. Two other studies re-
port the cytotoxic activity of the petroleum-ether bark extract 
of T. arjuna against hepatocellular carcinoma (HEPG2) and 
colorectal adenocarcinoma (HT-29) cell lines [62], and the 
cytotoxic effects of an ethanolic extract of T. arjuna on 
HEPG2 cells through apoptosis induction [63]. To the best of 
our knowledge, this latter investigation is the only work which 
explored the anticancer potential of an ethanolic extract from 
the bark of T. arjuna and reported research findings similar 
to that of our study, even if in a different tumour cell line. 
 Furthermore, other studies investigated the antitumor 
potential of different compounds isolated from the bark of T. 
arjuna, such as casuarinin, a hydrolysable tannin, arjunic 
acid, and arjunolic acid, two triterpenoids. Casuarinin has 
been shown to induce apoptosis in A549 human non-small 
lung carcinoma cells and in MCF-7 human breast adenocar-
cinoma cells by activating the Fas/APO-1 apoptotic pathway 
[64, 65]. Arjunic acid, instead, showed significant cytotoxic-
ity in human non-small lung carcinoma cells (NCI-H460), 
colorectal adenocarcinoma cells (HT-29), and acute lym-
phoblastic leukaemia cells (CEM) [66]. Additionally, Joo 
and colleagues reported that arjunic acid cleaves Poly ADP-
ribose polymerase (PARP), activates Bax and p-JNK (c-Jun 
N-terminal kinase), and reduces the expression of pro-
caspase 3 and Bcl-2 on A549 and NCI-H460 cells [67]. 
Moreover, in vitro and in vivo apoptotic induction by arjuno-
lic acid was observed on Ehrlich ascites carcinoma cells by 
 
Fig. (2). Percentage (%) of living, apoptotic, and necrotic cells after 24 h treatment of Jurkat cells with increasing concentrations of TAEE.  
** p < 0.01; *** p < 0.001 versus untreated cells.  
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Elsherbiny and coworkers [68]. For casuarinin, arjunic acid, 
and arjunolic acid no induction of necrosis was recorded. 
 We investigated the antitumor properties of a crude plant 
extract, representing a phytocomplex, wherein a mixture of 
different compounds contributes to its biological activity. 
Many natural products could result in activities that later 
vanished when they are separated into individual chemical 
components [69]. It is interesting to note that in our study we 
observed that TAEE induces necrosis, not only apoptosis. 
The different activity of TAEE could be due to the fact that 
other components may lead to additional biological activi-
ties, such as TAEE-induced necrosis, which has not been 
observed for casuarinin, arjunic acid and arjunolic acid iso-
lated from T. arjuna bark. 
3.4. TAEE Causes Cell-Cycle Perturbations 
 In the following experiments, we highlighted the cy-
tostatic effect of TAEE. The treatment with increasing con-
centrations of TAEE increased the number of cells in the 
G2/M phase. Starting from the concentration 0.80 mg/mL, 
the accumulation of cells in G2/M phase appeared to be sta-
tistically significant, with 42% versus 29% of untreated 
cells; at the highest tested concentration, the percentage fur-
ther increased to 47%. This observed increase was accompa-
nied, at all tested concentrations, by a slight compensatory 
decrease in the G0/G1 phase (from 55% of untreated cells to 
38% at 1.00 mg/mL) (Fig. 3). 
 Cell cycle takes place over four phases: G1 (gap), S (syn-
thesis), G2 (gap) and M (mitosis), and is finely regulated by 
cyclins and cyclin-dependent kinases (CDKs), which facili-
tate chromosome replication and separation, and cytokinesis 
[70]. CDKs bind cyclins, their regulatory sub-components, 
which are synthesized and destroyed at specified times 
throughout the cell cycle, thereby controlling kinase activity 
[71]. Normally, the G1/S and G2/M checkpoints control cell 
proliferation accurately; cell-cycle arrest is thus considered 
one of the most common triggers of cell proliferation inhibi-
tion [72]. 
 Even if the replication system is highly preserved, in the 
last two decades, a broad range of literature highlighted the 
importance of cell-cycle deregulation over human cancer 
[71]. Cancer cells are characterized by genomic and chromo-
somal instability; accumulation of mutations leads to cell-
cycle deregulation, uncontrolled proliferation, and tumour 
progression [71, 73, 74]. Thus, agents able to perturb cell-
cycle progression could be considered as effective therapeu-
tic drugs for cancer treatment. Additionally, cancer cells can 
survive mitotic arrest induced by antimitotic drugs and pre-
vent subsequent cell death, which is considered an active 
mechanism of chemoresistance [75]. Thus, the cytotoxic 
effect exhibited by TAEE along with cell-cycle arrest could 
result in an improved strategy to eradicate tumour cells. 
 As far as we know, no other authors have investigated the 
ability of T. arjuna extract to arrest cell cycle. Kuo and col-
leagues, however, found that casuarinin blocks cell-cycle 
progression in the G0/G1 phase in MCF-7 cells [65] and in 
A-549 cells [64]. As we observed that TAEE induces a cell-
cycle block in the G2/M phase, our findings are in contrast 
with the aforementioned studies. This different result could be 
due to the fact that the extract contains many active compounds 
other than casuarinin or could be a cell-type-specific effect. 
3.5. TAEE Is Not Genotoxic 
 In order to evaluate the ability of TAEE to induce DNA 
damage, H2A.X analysis was performed. Phosphorylation of 
H2A.X (P-H2A.X) at Ser 139 is considered an early cellular 
response to DNA double-strand breaks. Thus, the analysis of 
this event is useful to detect the ability of a compound to 
induce DNA damage. After 6 h of treatment with TAEE, no 
significant increase in H2A.X phosphorylation was observed 
at any tested concentration, thus excluding any genotoxic 
activity of the extract (Fig. 4). 
 Hence, to definitely establish the non-genotoxic potential 
of TAEE, we analyzed the frequency of MN after TAEE 
treatment. Unlike the phosphorylation of H2A.X assay, 
through which it is possible to observe only clastogenic ef-
 
Fig. (3). Cell‐cycle distribution following 24 h treatment of Jurkat cells with increasing concentrations of TAEE. *** p < 0.001 versus un-
treated cells.  
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fects (i.e. breakages of chromosomes), the micronucleus test 
is able to detect both clastogenesis and aneuploidy (i.e. 
changes in chromosome number) [76]. TAEE did not in-
crease the MN frequency, thus confirming its non-genotoxic 
activity (data not shown). 
3.6. TAEE Does Not Exert Protective Effect Against 
Genotoxic Damage 
 The most common and widely distributed classes of sub-
stances in the plant kingdom are phenolic compounds or 
polyphenols, that actually include over 8,000 phenolic struc-
tures [77]. As products of secondary plant metabolism, poly-
phenols play an essential role in plant growth and metabo-
lism regulation, and protection of plant against UV radiation 
and various pathogens [78]. In addition, they are able to in-
hibit different steps involved in the carcinogenetic process 
[79, 80]. In particular, polyphenols are able to reduce the 
expression of phase I enzymes, involved in carcinogens 
activation, and increase the expression of phase II 
detoxification enzymes, thus acting as blocking agents [81]. 
Moreover, several studies have documented their ability to 
act also as suppressing agents by inhibiting cell proliferation 
[82], inducing apoptosis [83, 84] and cell-cycle arrest [85, 
86], and blocking neoangiogenesis [87-90]. 
 Polyphenols have also shown protective activity against 
DNA damage induced by physical and chemical agents, and 
chemotherapeutic drugs [91, 92]. Elevated levels of reactive 
oxygen species (ROS) are one of the major causes of DNA 
damage. Because of their antioxidant potential, phenolic 
compounds inhibit oxidative damage to cellular DNA [93]. 
Besides the antioxidant activity, many other mechanisms are 
considered to be implicated in the antigenotoxic effects of 
polyphenols, such as modulation of DNA synthesis and re-
pair, binding to mutagens, effects on mutagen adsorption, 
and modulation of xenobiotic metabolizing enzymes [94] 
Bearing these considerations in mind and taking into account 
that the total polyphenolic content has been shown to repre-
sent about the 60 % of the T. arjuna ethanolic extract, we 
investigated the ability of TAEE to protect cells against the 
genotoxicity of two different genotoxic agents: hydrogen 
peroxide (H2O2) and etoposide. H2O2 causes oxidative DNA 
damage by the formation of hydroxyl peroxide (·OH-). Hy-
droxyl peroxide attacks the deoxyribose moiety of DNA and 
generates DNA single-strand and double-strand breaks, and 
the formation of 8-oxo-7,8-dihydroguanine and abasic sites 
[95, 96]. Etoposide induces DNA damage by forming a 
complex with topoisomerase II and DNA, which results in an 
increase in double-stranded DNA breaks [97]. In order to 
investigate the antigenotoxic effects of TAEE, two different 
experimental settings were used: pre-treatment of Jurkat cells 
with TAEE for 3 h and then treatment with genotoxicants; 
co-treatment of 1 h with TAEE and genotoxicants. As shown 
in Fig. 5, the results obtained indicate that TAEE did not 
exert any protective effect against the genotoxicity of 
etoposide and H2O2, either using pre-treatment or co-
treatment experimental protocol. 
 Howewer, very few studies have been carried out on the 
antigenotoxic activity of T. arjuna. Kaur and colleagues 
[98], for example, studied the protective effect of a tannin 
fraction isolated from T. arjuna against the genotoxicity of 
4-nitro-o-phenylenediamine, sodium azide, and 2-
aminofluorene using the Ames assay. The tannin fraction 
was highly effective only towards 2-aminofluorene, thus 
showing that the protective effect is dependent on the geno-
toxic tested [98]. Additionally, Pasquini et al. investigated 
the antigenotoxic potential of T. arjuna bark against the 4-
nitroquinoline-N-oxide genotoxicant, using different in vitro 
tests (i.e. Salmonella/microsome test, comet assay and mi-
cronucleus test) [99]. In this study, the bark of T. arjuna was 
extracted sequentially with six solvents with decreasing hy-
drophobicity (i.e. chloroform, acetone, methanol, metha-
nol+HCl, diethyl ether, and ethyl acetate). Among the six 
tested extracts, authors found a significantly different activ-
ity that has been shown to be related to the extraction solvent 
used: indeed, among them, the acetone extract was the most 
effective in reducing genotoxic activity while the methanol, 
ethyl acetate, and chloroform extracts exhibited a different 
inhibitory activity depending on the test used; conversely, the 
diethyl ether and the acid methanol extracts lacked or showed 
the lowest inhibitory effect against the tested genotoxicant [99]. 
 A substantial difference that can be observed between 
our paper and the above mentioned papers is the different 
type of extract used in the studies: we tested a raw extract in 
which the presence of any active molecules could be much 
less concentrated than, for example, the tanninic fraction 
tested by Kaur and colleagues [98]; in addition, the study by 
Pasquini et al. [99] tested different types of extracts of T. 
arjuna, but not the ethanolic. Different solvents extract dif-
ferent phytochemicals, which can be responsible for the bio-
logical activity of the extract. 
 Moreover, we have tested the antigenotoxic activity of 
TAEE against two genotoxicants acting with a mechanism  
of action different from those used in the studies reported 
above (i.e. 4-nitroquinoline-N-oxide [99] and 4-nitro-o-
phenylenediamine, sodium azide, and 2-aminofluorene [98]). 
This means that the extract can exert protective effects only 
against compounds with a specific genotoxic mechanism. 
 However, although TAEE has not shown any genopro-
tective activity, the lack of genotoxic effects demonstrates its 
 
Fig. (4). Relative expression of phosphorylated H2A.X (P-H2A.X) 
induced by TAEE in Jurkat cells after 6 h of treatment. Etoposide 
(10 µM) was used as positive control. *** p < 0.001 versus untreated 
cells.  
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favourable toxicological profile. The ability of a substance to 
induce DNA damage is a critical element in defining its tox-
icity as DNA alterations are implicated in the pathogenesis 
of several chronic degenerative diseases such as cancer 
[100], cardiomyopathies and atherosclerosis [101], glaucoma 
[102], and neurodegenerative diseases [103]. Moreover, 
genotoxicity is a dose-independent event for which it is not 
possible to define a range of concentrations where the effect 
does not occur [100]. 
CONCLUSION 
 Despite significant advances, current anticancer therapies 
still have limited effectiveness, mainly due to their low 
therapeutic index and the frequent appearance of chemoresis-
tance. Hence, there is a compelling need to develop new in-
tervention strategies. Considering their unique features, natu-
ral compounds could be considered excellent candidates for 
this purpose. Taken together, the results of this study suggest 
that the ethanolic extract obtained from the bark of T. arjuna 
exerts toxic effects on human leukaemia cells. These toxic 
effects have been shown to be related to the ability of the 
extract to induce cell death by both apoptosis and necrosis 
and block cell-cycle progression in the G2/M phase. Addi-
tionally, it was found that TAEE lacks any genotoxic effect 
and is not cytotoxic for non-tumorigenic cells, hence assum-
ing a favourable toxicological profile. Our findings increase 
the growing body of literature on the antitumor activity of 
this medicinal plant, thus confirming the pivotal role played 
by natural compounds in the oncological field. Further stud-
ies should be performed to better understand its clinical po-
tential and deepen its toxicological profile. 
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